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ABSTRACT 
Background: In pre-eclampsia, immune maladaptation to the foetal allograft results in 
impaired trophoblast invasion and defective spiral arterial remodelling with consequential 
placental oxidative stress. Placental apoptosis can be initiated by various stimuli including 
hypoxia and oxidative stress and is notably exaggerated in pre-eclampsia. This elevated 
apoptosis prevents normal replenishment of the syncytiotrophoblast, promotes syncytial 
degeneration and releases vasoactive or inflammatory factors into the maternal circulation 
thereby provoking the endothelial dysfunction seen in pre-eclampsia. Since the p53 antigen 
and JNK are important mediators of apoptosis we determined their expression in HIV 
associated pre-eclampsia.  
Method: Blood samples were collected from normotensive pregnant and pre-eclamptic HIV 
infected and negative women. Buffy coat was extracted and a Bio-plex multiplex assay to 
quantify expression of phosphorylated-p53 and JNK.  
Results: Based on pregnancy type, a significant difference in the expression of p53 was noted 
between the pre-eclamptic vs normotensive pregnant group regardless of HIV status 
(p=0.0162). Irrespective of pregnancy type, there was also a significant difference found 
between the HIV positive and HIV negative groups (p=0.0469). Furthermore, there was a 
significant difference in the expression of p53 between the HIV negative pre-eclamptic vs the 
HIV negative normotensive group and HIV infected normotensive vs the HIV negative pre-
eclamptic group. Despite having no statistical significance (p=0.8701), the expression of JNK 
was found to be increased in the pre-eclamptic compared to the normotensive pregnant group. 
Similarly, based on HIV status, regardless of pregnancy type no statistical significance was 
found (p=0.2227), however, there was a decrease in the expression of JNK in the HIV positive 
compared to the HIV negative group.  
xiii 
 
Conclusion: These experiments demonstrate a significant increase in the expression of p53 
with an upwards trend in the expression of JNK in pre-eclampsia, confirming their influence 
on trophoblast cell invasion in pre-eclampsia development. This increase in expression of p53 
and JNK in pre-eclampsia, holds potential value as a risk indicator of pre-eclamptic 
development. In contrast, a significant down regulation of p53 with a downwards trend of JNK 
expression was noted in the HIV positive group, possibly due to immune reconstitution 
following HAART.
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1.0 BACKGROUND AND LITERATURE REVIEW 
1.1 Maternal Mortality 
Globally, the rate of maternal mortality is high. Every day, there are about 830 maternal deaths due to 
pregnancy or childbirth related complications worldwide, with 99% of all maternal deaths occurring in 
developing countries (Alkema et al., 2016). In 2015, it was estimated that approximately 303, 000 
women died during and following pregnancy and childbirth, most of these deaths were preventable 
(Alkema et al., 2016). 
In South Africa, during 2011-2013 there were 4452 maternal deaths. The top three causes of maternal 
death were: non-pregnancy related infections (mainly HIV infected pregnant women), obstetric 
haemorrhage and hypertension which accounted for 34.7%, 15.8% and 14.8% maternal deaths 
respectively. Majority (67%) of the cases of maternal deaths emanating from hypertension was 
preventable (South African Department of Health, 2013). 
1.2 HIV 
Human Immunodeficiency Virus (HIV) infection remains one of the leading health concerns in the 
world. In 2015, roughly 2.1 million new infections were reported worldwide, with a recent tally of 36.7 
million people living with HIV infection (UNAIDS, 2016). In South Africa, the overall HIV prevalence 
rate is estimated to be 12.7%. For adults of reproductive age (15–49 years), an estimated 18.9% of the 
population is HIV infected (Statistics South Africa, 2016). 
HIV is a retrovirus that can integrate its DNA into the host genome (Craigie and Bushman, 2012). The 
primary receptor for HIV-1 is CD4+. The CD4+ cell is expressed on the surface of T lymphocytes, 
monocytes, and macrophages (Février et al., 2011). HIV can be transmitted through infected body fluids 
that come into contact with mucosal tissue, blood or broken skin (Deeks et al., 2015). HIV causes 
progressive loss of CD4+ T cells, which results in a decline of cell-mediated immunity (Moir et al., 
2011, McCune, 2001). This renders the individual vulnerable to a range of opportunistic infections 
(Holmes et al., 2006). 
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Management of HIV infection includes the use of multiple antiretroviral drugs. Highly active 
antiretroviral treatment (HAART), is a powerful therapy which suppresses HIV replication and allows 
partial restoration of CD4+ T cell populations. (Schmidt-Westhausen et al., 2000, Ramirez-Amador et 
al., 2003, Février et al., 2011). 
1.2.1 HIV and women 
Currently, one-fifth of South African women in their reproductive ages are HIV infected (Statistics 
South Africa, 2016). Women are more likely to face increased tissue injury and due to their anatomy 
have a larger mucosal surface area, resulting in longer exposure times to pathogens and infectious fluid 
during sexual intercourse. Thus, the women have a higher physiological risk of infection (Ackermann 
and Klerk, 2002). 
During pregnancy, the high levels of oestrogen and progesterone may alter the genital mucosa structure, 
alternatively it can cause immunological changes including increased mucosal lymphoid aggregates or 
the up-regulation in the expression of co-receptors that are involved with HIV infection (Chersich and 
Rees, 2008). HIV infection and hypertensive disorders of pregnancies, especially pre-eclampsia are 
important conditions in developing countries (Hall et al., 2014). 
1.3 Pre-Eclampsia 
Pre-eclampsia (PE) is a condition specific to pregnancy that occurs after the 20th week of gestation 
(Silasi et al., 2010) and is characterized by new-onset hypertension (high blood pressure), with 
proteinuria. PE is defined as a blood pressure reading of ≥ 140/90 mmHg on two or more occasions 
after the 20th week of pregnancy with significant proteinuria >300mg/dl present in a 24-hour period 
(Davey and MacGillivray, 1988). It is estimated that 3-5% of all pregnancies are affected worldwide by 
PE, making it the most common pregnancy complication (Wang et al., 2009), and a leading cause of 
perinatal and maternal morbidity and mortality (Levy, 2005). 
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Some of the risk factors of PE include; primigravidae, a maternal and paternal family history of PE, 
nulliparity as well as pre-existing metabolic disorders such as diabetes, chronic hypertension, obesity 
and kidney disease (Silasi et al., 2010). 
1.3.1 Complications of pre-eclampsia 
Maternal complications of PE include; acute renal failure, placental abruption, seizures, pulmonary 
oedema and the HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome (Wang et 
al., 2009). When vascular dysfunction of the brain occurs, eclampsia can develop which is characterized 
by seizures (Coppage and Sibai, 2005). Complications which affect the developing foetus include; 
prematurity (Zhang et al., 2007), intrauterine foetal growth restriction and an increased risk of perinatal 
death (Wang et al., 2009). Increased maternal and foetal morbidity and mortality are largely due to a 
lack of predictive biomarkers and effective pharmaceutical interventions (Tannetta and Sargent, 2013). 
There is no treatment for PE currently, except early delivery of the placenta and the baby, however this 
increases the risk of neonatal morbidity and mortality (Williamson et al., 2017).  
1.3.2 The placenta  
The placenta is fundamental to the pathogenesis of PE, as PE only occurs when the placenta is present, 
even when there is no foetus, as in a hydatidiform molar pregnancy. The maternal symptoms of PE 
usually resolve when the placenta is delivered (Naljayan, 2013). The placenta is a fetally-derived 
multifaceted organ which connects the developing foetus to the uterine wall providing nutrition, 
removal of waste products, performing endocrine functions and affording foetal protection from the 
maternal immune system (Gude et al., 2004). Altered placental development and function can have 
repercussions on the foetus affecting its ability to cope with the intrauterine micro-environment (Gude 
et al., 2004).  
1.3.3 Placentation 
During implantation, the secretion of hormones regulate growth factors, cytokines and adhesion 
molecules, thereby altering the endometrial surface and opening the implantation window. Following 
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attachment, the trophoblast layer of the blastocyst proliferates rapidly and differentiates (Gude et al., 
2004).  
Cytotrophoblast cells differentiate into; the multinucleate syncytiotrophoblast and the invasive extra-
villous trophoblast cell populations. Syncytiotrophoblasts cover the surface of the placenta and allow 
foetal-maternal exchange, while also secreting hormones into the maternal circulation necessary for the 
maintenance and immunological adaptation of pregnancy (Bansal et al., 2012, Gude et al., 2004). It has 
been proposed that fusion between the cytotrophoblasts and the syncytiotrophoblast is a means of 
replenishment of the syncytiotrophoblast (Sharp et al., 2010). The extravillous trophoblasts invade the 
uterine spiral arteries of the decidua and myometrium in a set timed sequence, replacing the endothelial 
layer of the maternal spiral arteries and transforming them from small, high-resistance vessels to high-
calibre capacitance, low resistance vessels that can sustain the growth of the foetus (Meekins et al., 
1994) (Figure 1). 
In normal placental development, intramural cytotrophoblasts differentiate from an epithelial phenotype 
to an endothelial phenotype by pseudovasculogenesis (Zhou et al., 1997). In PE, failure to adopt an 
invasive endothelial phenotype in cytotrophoblasts is observed (Zhou et al., 1997).  
1.3.4 Pathogenesis of pre-eclampsia 
The exact pathophysiology of PE remains unknown. In PE, the physiological conversion of the spiral 
arteries is incomplete and is limited to the decidua (Meekins et al., 1994). Failure of trophoblast invasion 
results in reduced uteroplacental perfusion which leads to the placenta becoming ischemic (Levy, 2005). 
Retention of vasoreactivity of the spiral arteries, could result in intermittent perfusion of the intervillous 
space, fluctuating oxygen tension, and ischemia-reperfusion injury of the villi (Hung et al., 2001). The 
re-established blood flow seen after placental reperfusion injury releases cytokines as well as other 
inflammatory factors and damaging levels of reactive oxygen species (Sánchez-Aranguren et al., 2014). 
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Figure 1. Normal vs Abnormal Placentation. In normal placentation (Left) the extravillous cytotrophoblasts 
invade the uterine spiral arteries of the decidua and myometrium, replacing the endothelial layer of the maternal 
spiral arteries, transforming them from small, high-resistance vessels to high-calibre capacitance vessels that can 
supply the necessary placental perfusion to sustain the growth of the foetus. In PE (Right) remodelling of the 
spiral arteries is inadequate and limited to the superficial decidua, with the myometrial segments remaining 
narrow. Figure adapted from (Lam et al., 2005).  
1.3.5 The role of the immune system in pre-eclampsia 
A common theory to explain the disease mechanism of PE is immune maladaptation to the foetal 
allograft (Dekker and Sibai, 1998). An exacerbated maternal inflammatory response directed against 
foreign foetal antigens can result in impaired trophoblast invasion and defective spiral arterial 
remodelling (Matthiesen et al., 2005). 
Contact between paternal antigens in the semen and the female genital tract through sexual intercourse 
allows for immune tolerance. However, when there is a new partner the risk of PE increases due to 
insufficient duration of exposure to sperm (Verwoerd et al., 2002, Hall, 2007b). 
The fetus and placenta is regarded as a semi-allograft to the mother’s immune system and therefore can 
produce an immune rejection response (Aagaard-Tillery et al., 2006). During early stages of pregnancy, 
there is an increased influx of macrophages and lymphocytes into the decidua at the maternal-foetal 
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interface (Bulmer and Johnson, 1985). A common theory is that human leukocyte antigen (HLA) G has 
an immunologically permissive function of the antigenic mismatch between mother and foetus, and this 
protects the developing foetus from these cells (Le Bouteiller et al., 2003). Defective HLA-G expression 
occurs in the extravillous cytotrophoblast of pre-eclamptic placentas. Serum levels of soluble HLA-G1 
isoform involved in the downregulation of T cell and NK cell activity by the induction of apoptotic 
events, are decreased in pre-eclamptic patients (Le Bouteiller et al., 2003).  
Notably, the Fas-FasL system could have a key role in the protection of the foetus from the maternal 
immune system (Pearson, 2002). Fas is a surface protein of the tumour necrosis factor (TNF) 
superfamily and can induce cell apoptosis upon binding to the ligand FasL (Griffith et al., 1995). FasL 
is expressed on the trophoblast of first-trimester placentas, and the Fas antigen is localized on decidual 
cells, specifically maternal leukocytes (Runic et al., 1996, Uckan et al., 1997). In-vitro, trophoblasts 
expressing FasL can induce lymphocyte apoptosis when exposed to activated lymphocytes (Hammer et 
al., 1999).  In PE, decidual cells have a lower expression of Fas antigen (Ishihara et al., 2002), and a 
lower expression of FasL (Allaire et al., 2000) is noted on trophoblast cells resulting in the diminished 
deletion of lymphocytes in the decidua with increased apoptosis and trophoblast damage (Levy, 2005). 
As a consequence of exaggerated apoptosis of the invading trophoblasts, limited invasion of the spiral 
arteries occurs (Levy, 2005).  
1.3.6 Immune maladaptation of pre-eclampsia and HIV infection 
In contrast to HIV infection, an up-regulation of the immune response occurs in normal pregnancy, 
however this up-regulation is exacerbated in PE producing an excessive maternal inflammatory 
response. Therefore, in HIV associated PE, a neutralisation of the immune response is expected (Hall 
et al., 2014). Studies are however conflicting and report an increased, decreased and a neutralisation of 
PE development in HIV associated pregnancies (Boyajian et al., 2012, Hall, 2007a, Kalumba et al., 
2013, Machado et al., 2014, Wimalasundera et al., 2002, Hall et al., 2014). 
In 2002, Wimalasundera and colleagues found that HIV-1 infected women who received no 
antiretroviral therapy had a significantly lower rate of PE development compared to HIV infected 
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women who were on triple antiretroviral therapy (Wimalasundera et al., 2002). They therefore proposed 
that women with untreated HIV infection are protected against PE development due to their 
immunocompromised state, they suggest that these women are unlikely to induce an exaggerated 
inflammatory response during pregnancy due to the progressive loss of CD4+ T lymphocytes. The 
administration of HAART in HIV infected women re-establishes the mother’s immune response to 
foetal antigens, and thus exacerbates the risk of PE development (Wimalasundera et al., 2002).  
Similarly, a cohort study by Suy and colleagues concluded that HIV infected women receiving HAART 
prior to pregnancy was associated with a higher risk of developing PE and was associated with greater 
foetal mortality (Suy et al., 2006). In contrast, PE and gestational hypertension were less prevalent in 
women receiving mono- or triple anti-retroviral therapy (Hall et al., 2014).  
Conflicting results were found in a study by Sansone and colleagues where HIV infected women had 
an increased risk of PE development, when receiving HAART (13%) and not receiving HAART (4.6%) 
compared to HIV uninfected women (4.1%) (Sansone et al., 2016). Whereas in a matched cohort study 
by Boyajian et al, no difference in the risk of developing PE was demonstrated between HIV infected 
women on HAART versus uninfected women (Boyajian et al., 2012). In South Africa, approximately 
30% of antenatal patients are infected with HIV (Sebitloane et al., 2009). It is therefore rational to study 
the effect of HIV infection on PE development.  
1.4 Oxidative stress 
Reactive oxygen species (ROS) include; nitric oxide (NO), superoxide (O2-), hydrogen peroxide (H2O2), 
and hydroxyl radical (·OH). These are signalling molecules implicated in the regulation of several 
functions in human physiology and are controlled by anti-oxidant host defences (Kalyanaraman, 2013). 
An increase in ROS generation during gestation is a physiological requisite (Yang et al., 2012). ROS 
are known as ‘secondary messengers’ in intracellular signalling cascades where the molecules control 
cell growth, proliferation and apoptosis (Thannickal and Fanburg, 2000).  
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A state of oxidative stress is observed when the relative pro-oxidant species is higher than the 
antioxidant defences (Sánchez-Aranguren et al., 2014). The increased generation of ROS could 
eventually trigger a redox signalling process that induces cell apoptosis (Sánchez-Aranguren et al., 
2014). 
1.5 Apoptosis and apoptotic pathways 
Apoptosis (programmed cell death), is vital in the normal development of the placenta however, when 
exaggerated it is associated with placental disease (Sharp et al., 2010). Apoptosis can be initiated via 
the extrinsic or intrinsic pathway. The extrinsic pathway is regulated by members of the TNF death 
receptor family (Straszewski-Chavez et al., 2005). Cellular stresses like DNA damage and ROS can 
initiate the intrinsic pathway. Activation of the intrinsic pathway leads to an altered mitochondrial 
membrane permeability due to an imbalance in the relationship of pro- and anti-apoptotic Bcl-2 proteins 
(Cory and Adams, 2002). Anti-apoptotic Bcl-2 members include; Bcl-2, Bcl-xL and Mcl-1 whilst pro-
apoptotic members include; Bax, Bak, tBid, Bim, Puma, Noxa and Bad (Vaseva and Moll, 2009). Bax 
and Bak convert into pore forming proteins by oligomerizing in the mitochondrial outer membrane. The 
lipid pores formed release fatal proteins from the mitochondrial inter-membranous space (Kroemer et 
al., 2007).  
tBid and Bim are activators which trigger mitochondrial outer membrane permeabilization (MOMP) by 
the direct stimulation of Bax and Bak oligomerization (Vaseva and Moll, 2009). Puma, Noxa and Bad 
are de-repressors which inhibit the anti-apoptotic Bcl-2 family members allowing the release of pro-
apoptotic members e.g., Bax or tBid from Bcl-xL (Vaseva and Moll, 2009, Kroemer et al., 2007).  
An increase in mitochondrial permeability results in pore formation and the leakage of cytochrome-c 
into the cytosol (Li et al., 1997). Cytochrome-c binds the apoptosis protease activating factor-1 (APAF-
1) (Ott et al., 2002) and the initiator caspase 9 in the cytosol forming the apoptosome complex 
(Chinnaiyan, 1999). This stimulates caspase 9, which activates the effector caspases. Furthermore, the 
protein Smac/DIABLO is also released from the mitochondrion into the cytosol which block the effects 
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of a group of anti-apoptotic proteins known as inhibitor of apoptosis proteins (IAPs), thereby indirectly 
promoting apoptosis (van Loo et al., 2002). 
Both the intrinsic and extrinsic pathways end in a terminal pathway involving the cleavage and 
activation of caspase-3, 6, and 7 initiating cell destruction by the activation of DNAses and cleaving 
DNA repair enzymes (Sharp et al., 2010, Tewari et al., 1995, Koh et al., 2005). Important cell signalling 
molecules involved in the regulation of apoptosis include tumour protein p53 (Prives and Hall, 1999) 
and c-Jun N-terminal protein kinase (JNK) (Lin and Dibling, 2002, Liu J and A., 2005). 
1.6 p53  
p53 is a transcription factor (Lane, 1992) mostly known for its activity as a tumour suppressor factor, 
however, it can also help to control a wide range of cellular processes and diseases. p53 has a critical 
role in the determination of cell fate by the activation of growth arrest, cellular senescence or apoptotic 
pathways (Brooks and Gu, 2010).  
p53 is an unstable protein with a short half-life, it is stabilized by hypoxia and oxidative stress (Levy, 
2005). Under normal conditions, the expression of p53 is kept at low levels to protect the cell from any 
uncontrolled activity. The ubiquitin ligase, murine double minute 2 (Mdm2) regulates the 
transcriptional activity of p53 by the direct inhibitory binding to p53, ubiquitination and enzymatic 
degradation of p53 by the proteasome as well as the nuclear export of p53 to the cytoplasm (Haupt et 
al., 1997, Kubbutat et al., 1997, Momand et al., 1992, Levine, 1997, Lu et al., 2000). p53 is further 
controlled by acting as a transcription factor for Mdm2, this promotes its own inhibition as part of an 
essential negative feedback loop (Harris and Levine, 2005).  
1.6.1 Activation of p53 antigen 
Cellular p53 increases rapidly post exposure to a variety of stressors including: heat, hypoxia, 
hyperoxia, and cytokines (Harris and Levine, 2005). These stresses promote DNA damage thereby 
activating repair enzyme activities (Harris and Levine, 2005). Following DNA damage, p53 becomes 
phosphorylated at several sites. ATM, JNK and ATR are some of the kinases able to phosphorylate 
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residues within the N-terminus of p53 in-vitro (Ashcroft et al., 1999). Phosphorylation of the N-
terminus allows for the stabilization of p53 by inhibiting the  p53-Mdm2 interaction (Kruse and Gu, 
2008) which allows for the expression of cellular p53 to increase. A series of post translational events 
need to occur for the activation of p53, of which phosphorylation may be a part of (Brooks and Gu, 
2010). The mechanism by which p53 either promotes cell growth arrest or apoptosis is poorly 
understood. Evidence suggests that the in-vivo function of p53 depends on the type and severity of 
damage that occurs (Brooks and Gu, 2010). 
1.6.2 Apoptotic pathways of p53 antigen 
p53 can induce apoptosis by the activation of gene expression in the nucleus, or by directly 
permeabilizing mitochondria in the cytoplasm (Wang et al., 2007). p53 is implicated in the induction 
of both the extrinsic and intrinsic apoptotic pathways (Susan Haupt et al., 2003).  
1.6.2.1 The role of p53 within the nucleus 
Activated p53 translocates from the cytosol to the nucleus (Liang and Clarke, 2001). p53 binds to a 
specific DNA target sequence, the responsive element (RE). Genes which contain the RE regulate the 
cell cycle and control cell fate (el-Deiry et al., 1992, Funk et al., 1992). 
Key targets of p53 include genes for pro-apoptotic proteins; Bax, Noxa, Puma, Bid and APAF-1 (Sharp, 
2011). p53 activates the intrinsic mitochondrial apoptotic pathway via the induction of the expression 
of at least three Bcl-2 pro-apoptotic members, disrupting the balance and allowing a shift towards pro-
apoptotic effects (Susan Haupt et al., 2003). (Figure 2). 
1.6.2.2 Mitochondrial effects of p53 
Activated p53 can initiate apoptosis without transcription or protein synthesis by migrating to the 
mitochondria. A proposed mechanism for this involves the direct interaction of p53 with the 
mitochondria (Mihara et al., 2003) where it acts like a pro-apoptotic Bcl-2 member either as a direct 
activator of Bax and/or Bak or as a de-repressor (Green and Kroemer, 2009). 
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Eventually the activation of p53 determines whether a cell enters a state of cellular senescence for DNA 
repair (Bhana et al., 2008, Chen et al., 2006, Dahm-Daphi et al., 2005, Sengupta et al., 2003) or p53 
initiates a cell death pathway leading to apoptosis. While controlled levels of p53 activity is needed for 
normal cell function, abnormal activation levels could be responsible for a variety of disease pathologies 
(Sharp, 2011) (Figure 2). 
1.6.3 Association of p53 in pre-eclampsia 
Placental p53 is present in normal pregnancy and in gestational trophoblast disease (Shi et al., 1996, 
Cheung et al., 1999). p53 has been found in cytotrophoblasts but hardly ever seen in the 
syncytiotrophoblast (Quenby S et al., 1998, Haidacher S et al., 1995). Whereas, Mdm2 is expressed 
within the cytotrophoblast and syncytiotrophoblast (Cheung et al., 1999, Fulop et al., 1998, Heazell et 
al., 2008b). An upregulation of p53 was found in placental and placental bed samples of pregnancies 
complicated by PE, with associated exaggerated apoptosis (Levy et al., 2002).  
 p53 expression in explanted human placental tissue is increased by hypoxia and is associated with 
exaggerated trophoblast apoptosis, which might reflect the in-vivo condition (Heazell and Crocker, 
2008). Furthermore, in response to decreased oxygen tension and ROS, there is an associated increase 
in p53 expression and the induction of apoptosis (Heazell et al., 2009). This suggests that hypoxia and 
ROS could be the causative mechanism in exaggerated placental apoptosis by the induction of p53 
activity in PE (Crocker, 2007) and that increased p53 expression in the placenta possibly plays a 
pathogenic role in PE development (Heazell et al., 2005).  
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Figure 2: Apoptosis Pathway in p53.Under normal circumstances p53 is bound inactive to Mdm2 within the 
cytoplasm. Post exposure to stress can cause the dissociation of p53 from Mdm2, allowing the phosphorylation 
and translocation of p53 to the nucleus. P53 forms a tetramer within the nucleus which facilitates DNA binding 
and the initiation of transcription of pro-apoptotic proteins such as Bax, Noxa, Puma, Bid and APAF-1. 
Alternatively, activated p53 could translocate to the mitochondria where p53 has been suggested to act as a direct 
activator of Bax and/or Bak or as a de-repressor. This eventually leads to formation of the apoptosome and 
apoptosis takes place. Adapted from (Heazell and Crocker, 2008). 
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1.7 JNK 
Mitogen activated protein kinases (MAPKs) are mediators in signal transduction pathways and are also 
involved in the differentiation of villous trophoblast (Qi and Elion, 2005, Vaillancourt et al., 2009). c-
Jun N-terminal protein kinase (JNK) is a subfamily of the MAPK superfamily (Liu J and A., 2005).  
They are associated with the regulation of cell proliferation, differentiation, and apoptosis. JNKs has a 
vital role in the mediation of apoptotic signalling (Dhanasekaran and Reddy, 2008). Studies have shown 
JNKs can be activated by various stimuli which include; growth factors (Hibi et al., 1993), cytokines 
(Westwick et al., 1994), and stress factors (Cano et al., 1994). 
JNK is able to phosphorylate and regulate the activity of transcription factors such as; c-Jun, ATF2, 
Elk-1, p53 and c-Myc (Chang and Karin, 2001, Davis, 2000, Karin, 1995, Lin, 2003) as well as other 
factors like the members of the Bcl-2 family (Bcl-2, Bcl-xL, Bim and BAD), when exposed to a wide 
range of extracellular stimuli (Liu J and A., 2005).  
1.7.1 Activation of JNK 
Specific stimuli trigger the activation of MAP3Ks, a member of MAP3K is primary apoptosis signalling 
regulated kinase 1 (ASK1) (Hayakawa et al., 2012) which can be activated by various stresses 
including, oxidative stress (Cindrova-Davies, 2009). This then phosphorylates and activates the 
MAP2K isoforms MKK4 and MKK7, which in turn phosphorylates and activates JNK. A key target of 
the JNK signalling pathway is the activator protein-1 (AP-1) transcription factor, which is activated 
partly due to the phosphorylation of c-Jun and associated molecules (Weston and Davis, 2002).   
1.7.2 Signalling of JNK in the regulation of apoptosis 
JNK signalling is a contributor to apoptotic signalling via phosphorylation of pro-apoptotic proteins.  
JNK participates in both the extrinsic and intrinsic signalling pathways that initiate apoptosis and can 
initiate apoptosis by nuclear and mitochondrial signalling (Dhanasekaran and Reddy, 2008). 
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1.7.2.1 Nuclear signalling of JNK in the regulation of apoptosis 
Following activation, the phosphorylated JNK translocates to the nucleus and phosphorylates and trans-
activates c-Jun (Davis, 2000, Chang and Karin, 2001). The phosphorylation of c-Jun results in the 
formation of AP-1. AP-1 is involved in the transcription of many proteins, including pro-apoptotic 
proteins (Dhanasekaran and L Johnson, 2007, Raman et al., 2007, Turjanski et al., 2007). The JNK-
AP-1 pathway is associated with the increased expression of pro-apoptotic genes like, TNF-α, Fas-L, 
and Bak (Fan and Chambers, 2001). Therefore, JNK can promote apoptosis by the increased expression 
of pro-apoptotic genes (Dhanasekaran and Reddy, 2008). Studies have shown that JNK can modulate 
the expression of p53 directly or indirectly and can positively influence apoptotic cell death (Saha et 
al., 2012). 
The phosphorylation of p53 at Ser6 by JNK stabilizes p53 by inhibiting ubiquitin-mediated degradation 
(Dhanasekaran and Reddy, 2008). Due to p53 being involved in the expression of pro-apoptotic proteins 
including Bax and PUMA, it is possible that the apoptotic pathway that is activated by JNK involves 
the upregulation of pro-apoptotic genes mediated by p53 (Dhanasekaran and Reddy, 2008). (Figure 3).  
1.7.2.2 Mitochondrial signalling of JNK in the regulation of apoptosis.  
JNK has a vital role in the modulation of the functions of the pro- and anti-apoptotic proteins found in 
the mitochondria. After activation by apoptotic stimuli, JNK translocates to the mitochondria 
(Kharbanda et al., 2000, Chauhan et al., 2003) where it modulates the activity of pro-apoptotic BH3-
only subgroup Bim and Bmf (Lei and Davis, 2003) and also promotes apoptosis by the inhibition of 
anti-apoptotic proteins like Bcl2 (Dhanasekaran and Reddy, 2008). (Figure 3).  
1.7.3 Association of JNK in Pre-eclampsia 
A study conducted by (Xiong et al., 2013) showed that an increase in the phosphorylation of p38 and 
JNK occur in human placental explants when exposed to a range of PE associated stress factors such as 
hypoxia and inflammatory cytokines. In vitro experiments involving placental villous explants exposed 
to hypoxia-reoxygenation (H/R) activates p38 and JNK stress pathways, and is associated with the 
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induction of apoptosis and inflammation (Cindrova-Davies et al., 2007). Also, it has been shown that 
in vitro, H/R and H2O2 treatment of placental villi can induce the activation of ASK1 (Cindrova-Davies, 
2009).   
 
Figure 3: JNK apoptotic pathways. Specific stimuli trigger the activation of MAP3Ks (ASK-1), this then 
phosphorylates and activates the MAP2K isoforms MKK4 and MKK7, this in turn phosphorylates and activates 
JNK. Phosphorylated JNK translocates to the nucleus and phosphorylates and transactivates c- Jun which results 
in the formation of AP-1. The JNK-AP-1 pathway is associated with the increased expression of pro-apoptotic 
genes like Bak. Alternatively, JNK translocates to the mitochondria where it modulates the activity of pro-
apoptotic BH3-only subgroup Bim. JNK can also promote apoptosis by the inhibition of anti-apoptotic proteins. 
Adapted from (Dhanasekaran and Reddy, 2008). 
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1.8 Association of apoptosis in pre-eclampsia 
In severe PE, cell turnover is dysregulated with a decrease in syncytiotrophoblast area (Huppertz and 
Kingdom, 2004), increased apoptosis (Leung et al., 2001, Allaire et al., 2000, Heazell et al., 2008a), 
and an increased density of syncytial nuclear aggregates (SNAs) (Jones and Fox, 1980, Heazell et al., 
2007). Morphometric image analysis has shown an increase in trophoblast cell apoptosis in PE (Naicker 
et al., 2013). Studies have shown that exaggerated apoptosis can be reproduced in trophoblast in vitro 
by exposure to hypoxia (Crocker et al., 2004) and reactive oxygen species (Moll et al., 2007).  
The role of enhanced apoptosis in the pathology of PE remains unclear. It could eventually prevent 
replenishment of syncytiotrophoblast, increase syncytial degeneration and release vasoactive or 
inflammatory factors into the maternal circulation (Sharp et al., 2014).  
1.9 Link between apoptosis and endothelial dysfunction 
The relationship between placental ischemia and endothelial cell dysfunction in the pathogenesis of PE 
remains unknown. Systemic endothelial damage seems to be the main theme in the signs and symptoms 
seen in PE. A theory proposed by (Redman and Sargent, 2000) suggests that systemic endothelial 
damage is caused by the microdeposition of syncytiotrophoblast microvillous membrane particles 
(STBMs) which can be detected in the plasma of normal pregnancies but are increased in women with 
PE (Nelson, 1996, Huppertz B et al., 1998). Increased syncytiotrophoblast deportation in PE could be 
produced by increased apoptosis at the syncytium (Huppertz B et al., 1998, Nelson, 1996) 
When STBMs are present within the maternal circulation, this has been associated with an altered 
immunological response, in specific, neutrophil activation (Von Dadelszen et al., 1999, Gupta et al., 
2006). Maternal levels of IL-1β, IL-6, and IL-8 are increased in PE (Luppi P and JA, 2006). In-vitro, 
STBMs can disrupt endothelial cells, supporting the connection between placental apoptosis, syncytial 
microparticle release and the maternal vascular complications, typical of the pre-eclamptic syndrome 
(Cockell et al., 1997, Hoegh et al., 2006). (Figure 4). 
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Figure 4. Sequence of events leading to pre-eclampsia.  
The exact pathophysiology of PE remains unknown. A common theory used to explain the disease mechanism is 
immune maladaptation leads to abnormal placentation which in turn causes reduced perfusion which can lead to 
oxidative stress. This results in an increase of regulatory components of apoptosis p53 and JNK, which 
consequently results in exaggerated apoptosis. This has been proposed to result in endothelial dysfunction and the 
clinical signs and symptoms of pre-eclampsia. With regards to HIV associated PE, this can neutralize the immune 
system.  
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1.10 Aim and Objectives of this study  
Aim of study 
To compare and contrast JNK and p53 levels across the study population based on pregnancy type (pre-
eclamptic vs normotensive) and HIV status (HIV Positive vs HIV negative).  
Specific Objectives 
•To determine the level of JNK in HIV associated normotensive and pre-eclamptic pregnant patients 
with the use of a BioPlex Multiplex immunoassay.  
•To determine the level of p53 in HIV associated normotensive and pre-eclamptic pregnant patients 
with the use of a BioPlex Multiplex immunoassay. 
•To compare and contrast JNK and p53 levels across the study population based on pregnancy type 
(pre-eclamptic vs normotensive) and HIV status (HIV Positive vs HIV negative).  
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Abstract 
Objective: Exaggerated apoptosis is associated with HIV infection and the pathogenesis of pre-
eclampsia, therefore the objective of this study was to determine expression of p53 and JNK in HIV 
associated pre-eclampsia.  
Method: This study used a Bio-plex assay to quantify expression of phosphprylated-p53 and 
phosphorylated-JNK in the buffy coat of HIV positive pre-eclamptic (n=20), HIV negative pre-
eclamptic (n=20), HIV positive normotensive pregnant (n=20), and HIV negative normotensive 
pregnant (n=20) women.  
Results: The expression of p53 significantly differed according to pregnancy type (pre-eclampsia vs 
normotensive; p=0.0162) and HIV status (HIV positive vs HIV negative; p=0.0469). There was also a 
significant difference in the expression of p53 between HIV negative pre-eclamptic vs HIV negative 
normotensive group (p < 0.05) and the HIV positive normotensive vs HIV negative pre-eclamptic group 
(p < 0.05). The expression of JNK, however showed no significant differences by pregnancy type 
(p=0.8701), HIV status (p=0.2227) and across study groups.  
Conclusion: An upregulation of p53 and JNK was found in pre-eclamptic women regardless of HIV 
status, suggesting a role in the pathogenesis of PE. Moreover, both p53 and JNK was downregulated in 
HIV infection regardless of pregnancy type. This suggests that HIV infection might confer a protective 
effect in pre-eclampsia development.  
Keywords: Pre-eclampsia, HIV, p53, JNK.  
Running title: p53 and JNK in HIV associated pre-eclampsia 
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Introduction 
Pre-eclampsia (PE) is defined as new-onset hypertension, with proteinuria occurring in the second half 
of pregnancy (1). It is a major cause of perinatal and maternal morbidity and mortality globally (2). The 
exact pathophysiology of PE remains elusive.  The most accepted concept is that immune maladaptation 
to the foetal allograft results in abnormal placentation, where cytotrophoblast invasion of the 
myometrium is shallow and remodelling of the uterine spiral arteries are incomplete (2-4). Abnormal 
placentation results in reduced perfusion which leads to hypoxia and subsequent ischemic reperfusion 
insult of the villus (2, 5), leading to the release of cytokines, other inflammatory factors and reactive 
oxygen species (ROS) such as superoxide dismutase (6). 
The increased generation of ROS triggers a redox signalling process that induces cell apoptosis (6). 
Apoptosis is important in the normal development of the placenta however, when elevated it hinders 
trophoblast invasion (7, 8). Moreover, a theory proposed by Redman and Sargent (9) suggests that 
systemic endothelial damage, the characteristic lesion of PE is caused by the increased deportation of 
syncytiotrophoblast microvillous particles (STBMs) due to increased apoptosis (10, 11).   
The precise mechanisms that stimulate apoptotic amplification in PE is unknown. Regulatory 
components of apoptosis include tumour protein p53 (12), and c-Jun N-terminal protein kinase (JNK) 
(13). p53 is a transcription factor (14) which has a critical role in determining cell fate by the activation 
of growth arrest, cellular senescence or apoptotic pathways (15). Under normal conditions, the 
expression of p53 is kept at low levels to protect the cell from any uncontrolled activity by the ubiquitin 
ligase, murine double minute 2 (Mdm2) (16, 17).   
Post exposure to stresses including: heat and hypoxia and cytokines DNA damage and activate repair 
enzyme activities are promoted (18). Following DNA damage, p53 becomes phosphorylated at several 
sites. ATM, JNK and ATR are some of the kinases able to phosphorylate residues within the N-terminus 
of p53 in-vitro (19). This enables the stabilization of p53 by inhibition of the p53-Mdm2 interaction 
(20) thus allowing for the expression of cellular p53 to increase. Phosphorylation may be a part of a 
series of post-translational events that occur prior to p53 activation (15). 
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The intrinsic apoptotic pathway involves the Bcl-2 family of proteins which influence cytochrome-c 
release from the mitochondria (21, 22). They include anti-apoptotic (Bcl-2, Bcl-xL and Mcl-1) and pro-
apoptotic (Bax, tBid, Bim, Puma, Bak, Noxa and Bad) members (23). p53 can induce apoptosis by 
either activating gene expression of pro-apoptotic proteins such as Bax, Noxa, Puma, Bid (16, 24) and 
Mtd (25) in the nucleus or by directly permeabilizing mitochondria in the cytoplasm by acting as a pro-
apoptotic BH3-only protein (26, 27). 
JNK is part of the mitogen activated protein kinases (MAPKs) superfamily, primarily involved in the 
regulation of cell proliferation, apoptosis and survival (28). They get activated through phosphorylation 
(29). JNKs can be activated by cytokines and exposure to environmental stress. Generally, the substrate 
of JNK is c-Jun however, they can also be involved in the activation of transcription factors like c-Myc, 
p53, and Elk-1 (28). JNK initiates apoptosis by the increasing the expression of pro-apoptotic genes in 
the nucleus like TNF-a, Fas-L, and Bak (30). Alternatively, activated JNK can translocate to the 
mitochondria where it modulates the activity of pro-apoptotic Bcl-2 proteins (31-34). 
In PE, a dysregulation of JNK (35) and p53 (36-38) has been observed. Studies have reported that HIV-
1 infection is capable of activating the MAPK signalling pathway (28). Activation of the MAPK 
signalling pathway can enhance the efficiency of HIV-1 infection (28). While p53 expression and 
activation has been associated with enhancing HIV disease progression, most likely through the 
induction of CD4 T cell death, and its cooperative effect in controlling viral gene transcription (39). 
There is however, a paucity of information on the level of both p53 and JNK in HIV associated 
pregnancy. 
In contrast to HIV infection, an upregulation of the immune response occurs in normal pregnancy, 
however, this up-regulation is exacerbated in PE producing an excessive maternal inflammatory 
response. Therefore, in HIV associated PE, a neutralisation of the immune response is expected (40).  
In light of the fact that the top three causes of maternal deaths in South Africa are non-pregnancy related 
infections (mainly HIV infected pregnant women complicated by tuberculosis and pneumonia; 34.7%,), 
obstetric haemorrhage (15.8%) and hypertension (14.8%) (41). The aim of this study is to determine 
the expression of JNK and p53 in HIV associated PE.  
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Methods and Materials 
Study Population 
This study received institutional ethical (BE204/17), Hospital manager’s and the Department of Health 
approval. The study was conducted at a large regional hospital that serves a mainly low socio-economic 
black South African population group.  
The study population consisted of a total of n=80 women categorized into HIV positive pre-eclamptic 
(n=20), HIV negative pre-eclamptic (n=20), HIV positive normotensive (n=20) and HIV negative 
normotensive (n=20). PE was defined as blood pressure reading of ≥ 140/90 mmHg on two or more 
occasions after the 20th week of pregnancy with the presence of significant proteinuria >300mg/dl in a 
24-hour period (42). All HIV positive women received dual anti-retroviral therapy i.e., highly active 
antiretroviral treatment (HAART) and nevirapine.   
The exclusion criteria for the PE group included: unknown HIV status, polycystic ovarian syndrome, 
chorioamnionitis, eclampsia, chronic hypertension, intrauterine death, abruption placentae, gestational 
diabetes, chronic diabetes, systemic lupus erythematous, chronic renal disease, sickle cell disease, 
thyroid disease, antiphospholipid antibody syndrome, cardiac disease, pre-existing seizure disorders 
and asthma. 
Bio-Plex Multiplex Method 
Maternal blood samples were centrifuged at 1200g for 10 minutes at 4°C, the buffy coat layer was 
aliquoted and used for the quantification of phosphorylated-p53 (S15) and phosphorylated-JNK 
(T183/Y185). A Bio-plex Pro Cell Signalling MAPK customised Panel 2-Plex Assay kit (#LQ0-
0000S6KL81S, Bio-Rad Laboratories, Inc., USA), was used according to the manufacturer’s 
instructions. UV-treated HEK-293 was used as a positive control while detection antibody diluent was 
used as a negative control. Samples were prepared in a 1:4 dilution. 
The immunoassay involved using capture antibody coupled beads, which were incubated with the 
antigen samples, i.e. phosphorylated-p53 and phosphorylated-JNK. Addition of biotinylated detection 
antibodies, and a reporter streptavidin-phycoerythrin conjugate (SA-PE) completed the interaction. 
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Samples were read using the Bio-Plex® MAGPIXTM Multiplex Reader (Bio-Rad Laboratories Inc., 
USA). The Bio-Plex ManagerTM software version 4.1 was used, and presented data as median 
fluorescence intensity (MFI). The relative concentration of analyte bound to each bead is proportional 
to the MFI of the reporter signal.  
Statistical Analysis  
Analysis of the data was done using Graphpad Prism 5.00 for Windows (GraphPad Software, San Diego 
California USA). Data is presented by mean ± standard error mean. A t-test was used to determine 
statistical significance according to pregnancy type (pre-eclamptic and normotensive) and HIV status 
(positive and negative), whilst a One-way ANOVA in combination with Bonferroni multiple 
comparison post-hoc test was used to determine statistical significance across all groups. Statistical 
significance was established when p < 0.05.  
 
Results  
Clinical Characteristics 
Table 1 shows a summary of the demographic data of the study population. Gestational age (p= 0.0009), 
parity (p= 0.0410) and systolic (p ˂ 0.0001) and diastolic (p ˂  0.0001) blood pressures were statistically 
different between the PE vs normotensive pregnant groups (T-test). Maternal age (p=0.8105) and 
maternal weight (p=0.1931) were similar between the PE vs normotensive pregnant groups. 
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Table 1. Patient demographics in the normotensive pregnant (n=40) and pre-eclamptic (n=40) 
groups 
 Normotensive 
(mean ± SEM) 
PE  
(mean ± SEM) 
p-value 
Maternal Age (years) 28 ± 0.91 30 ± 2.50 0.8105 (ns) 
Gestational Age 
(weeks) 
38 ± 0.18 35 ± 0.70 0.0009 
(***) 
Parity 1.5 ± 0.19 2.0 ± 0.17 0.0410 (*) 
Systolic BP (mmHg) 109 ± 3.70 154 ± 2.40 ˂0.0001(***) 
Diastolic BP (mmHg) 69 ± 2.80 100 ± 1.30 ˂0.0001(***) 
Weight (kg) 80 ± 2.00 85 ± 2.90 0.1931 (ns) 
Results are represented as the mean ± standard error mean (SEM), ns: non-significant 
* - p < 0.05  
*** - p < 0.001 
Median Fluorescent Intensity (MFI) of p53 and JNK. 
The MFI of p53 and JNK are shown in Table 2 and figure 1 (A-C) and 2 (A-C).  
p53 expression: 
Based on pregnancy type, a significant difference in the expression of p53 was noted between the PE 
vs normotensive pregnant groups (p=0.0162), regardless of HIV status (HIV positive vs HIV negative). 
A higher expression was demonstrated in the PE (24±1.30 MFI) compared to the normotensive pregnant 
(20 ± 0.80 MFI) group (Figure 1A).  
Based on HIV status, there was a significant difference in the expression of p53 between the HIV 
positive vs HIV negative groups (p=0.0469), irrespective of pregnancy type (pre-eclamptic vs 
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normotensive pregnant). A lower expression was observed in the HIV positive (20 ± 0.60 MFI) 
compared to the HIV negative (23 ± 1.40 MFI) group (Figure 1B). 
There was a significant difference (p < 0.05) in the expression of p53 between the HIV negative pre-
eclamptic (26 ± 1.60 MFI) vs HIV negative normotensive (20 ± 1.80 MFI) group and the HIV positive 
normotensive (20 ± 0.72 MFI) vs HIV negative pre-eclamptic (26 ± 1.60 MFI) group, (p < 0.05) (Figure 
1C). 
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Figure 1. MFI of cell signalling factor p53: (A) p53 based on pregnancy type, (B) p53 based on 
HIV status and (C) p53 across all groups. The MFI of p53 was significantly different based on 
pregnancy type (*; pre-eclamptic vs normotensive) regardless of HIV status and based on HIV 
status (*; HIV positive vs HIV negative) regardless of pregnancy type. There was also a significant 
difference in the MFI of p53 between HIV negative pre-eclamptic vs HIV negative normotensive 
(*), and between HIV positive normotensive vs HIV negative pre-eclamptic (*).  
Results are represented as mean ± standard error mean (SEM).  
* - p < 0.05.  
JNK expression: 
Based on pregnancy type. The expression of JNK was similar between pre-eclamptic vs normotensive 
pregnant groups (p=0.8701), regardless of HIV status (HIV positive vs HIV negative). Despite having 
no statistical significance, the expression of JNK was increased in the pre-eclamptic (26 ± 3.20 MFI) 
compared to the normotensive pregnant group (25 ± 2.00 MFI) (Figure 2A).  
Based on HIV status, the expression of JNK was similar in the HIV positive vs HIV negative groups 
(p=0.2227), regardless of pregnancy type (pre-eclamptic vs normotensive). There was also a decrease 
in the expression of JNK in the HIV positive group (24 ± 2.70 MFI) compared to the HIV negative (26 
± 2.20 MFI) group (Figure 2B).  
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No significance in the expression of JNK was demonstrated across all study groups, HIV positive pre-
eclamptic, HIV negative pre-eclamptic, HIV positive normotensive and HIV negative normotensive 
(Figure 2C).  
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Figure 2. MFI of cell signalling factor JNK: (A) JNK based on pregnancy type, (B) JNK based on 
HIV status and (C) JNK across all groups. No significant difference was found in the MFI of p53 
based on pregnancy type (pre-eclamptic vs normotensive) regardless of HIV status and based on 
HIV status (HIV positive vs HIV negative) regardless of pregnancy type. There was also no 
significant difference across all groups. 
Results are represented as mean ± standard error mean (SEM).  
Table 2 MFI of p53 and JNK across all study groups. 
 Normotensive Pregnant (n=40) Pre-eclamptic Pregnant (n=40) 
 HIV negative  HIV positive HIV negative  HIV positive 
p53 20 ± 1.80 20 ± 0.72 26 ± 1.60 21 ± 1.20 
JNK 27 ± 2.40 23 ± 3.30 25 ± 4.40 29 ± 5.00 
Results are represented as the mean ± standard error mean (SEM). 
Discussion 
This study has demonstrated a significant increase in the level of p53 in women with PE compared to 
normotensive pregnant women.  This observation in pre-eclamptic women, is consistent with previous 
reports albeit using placental tissue samples (36, 38). Notably, the hypoxia and oxidative stress that 
occurs in PE, expounds the exaggerated syncytiotrophoblast autophagy and apoptosis that characterises 
PE (36). In support of this, studies have shown an association between exposure of trophoblasts to 
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hypoxia and enhanced apoptosis (43) with an increase in the expression of p53 (43), Bax (43), and Mtd-
1 (44) with a simultaneous decrease in Bcl-2 expression (43, 45).  
In our study, we also report no significant difference, albeit an upwards trend in JNK expression 
between pre-eclamptic compared to normotensive pregnancies. Our results are corroborated by Szabo 
et al (35) who evaluated JNK immunostaining of the villous trophoblast and demonstrated that there 
was no change in JNK immunoscores in preterm or term PE. However, an upregulated trend was noted 
in late-onset PE compared to term controls. This increase could be attributed to the increased hypoxia 
and oxidative stress secondary to defective placentation that occurs in PE (7). Studies in support of this 
theory show that placental explants challenged with different pre-eclamptic associated stresses such as 
hypoxia-reoxygenation (H/R) (46), hypoxia and inflammatory cytokines (47) lead to in increased 
oxidative stress and subsequent phosphorylation of JNK with the resultant activation of the JNK/MAPK 
pathway (46, 47). The antioxidant vitamins C and E effectively suppress markers of oxidative stress, 
apoptosis as well as phosphorylation of JNK induced by H/R (46). 
Notably, plasma hydrogen peroxide (H2O2) levels are increased in women with PE (48). Tang and 
colleagues (49) found H2O2 treatment decreased the viability, triggered apoptosis and increased 
phosphorylation of JNK of human trophoblast like cell line JEG-3 cells whilst the addition of a JNK 
inhibitor SP600125 increased cell viability and decreased apoptosis (49). Thus, it is plausible to assume 
that both hypoxia and oxidative stress contribute to the increase of p53 and JNK in the causation of the 
exaggerated apoptosis in PE.   
In our study, we demonstrate a significant decrease of p53 expression in HIV positive compared to HIV 
negative individuals, regardless of pregnancy type. This observation may be attributed to the 
neutralisation of the immune response expected in HIV associated PE (40). Furthermore, the HIV-1 
accessory protein, Nef directly interacts with p53, with consequential destabilization of p53, decreasing 
its half-life, proapoptotic, transcriptional, and DNA binding activities (50). This demonstrates that Nef 
could supplement HIV replication by extending infected cell sustainability by blocking p53-mediated 
apoptosis (50). This indicates that HIV infection may have a protective effect by reducing the level of 
p53, hence preventing PE development.  
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However, in contrast to these observations, previous studies report that p53 is activated in HIV-1 
infection (39). Our results may be due to the use of HAART which suppresses HIV replication (51). 
Moreover, a significant difference of p53 was found in HIV positive normotensive vs the HIV negative 
pre-eclamptic group.  
Based on HIV status, we also report no significant difference in the JNK expression. Previous studies 
have shown that HIV-1 infection could activate the host cellular MAPK signalling pathway, this could 
enhance HIV-1 gene expression level, viral genome replication level and virus infection activity (52-
54). A study by Gong et al (28) showed that a JNK pathway inhibitor SP600125 had an effect on HIV 
infection and HIV-1 LTR promoter activity (28).   
One should also take cognisance of the fact that all HIV infected women in our study were on HAART 
or anti-retroviral drugs (nevirapine).  The administration of HAART in HIV infected women has been 
linked to increased predisposition to PE development (55, 56) as it causes immune reconstitution (57). 
Lower activation levels of JNK, AKT and ERK kinases have been observed post HAART treatment 
(51), thereby indicating HAART may be responsible for the decreased p53 and JNK levels in HIV 
infected individuals.  
Usually, the syncytiotrophoblast is protected against apoptosis, by the expression of various anti-
apoptotic proteins including: Mdm2, Bcl-2, and Mcl-1 which antagonize the effects of pro-apoptotic 
p53, Bax, Bak, Mtd and smac (58-61). However, in PE, Sharp et al (36) have shown a substantial 
reduction in the anti-apoptotic protection of the syncytiotrophoblast with a decrease in Mdm2. This 
therefore facilitates an increase in p53 expression culminating in a pro-apoptotic environment. The loss 
of function of Mdm2 is also related to increased apoptosis and syncytial degeneration (36). 
In PE, intrinsic cell damage has been proposed to lead to increased levels of apoptosis, hypothesized 
in vivo to stem from hypoxia-reperfusion injury (62), and replicated in vitro by hypoxia (38, 60, 63) and 
oxidative stress (64, 65). The role that exaggerated apoptosis plays in the pathogenesis of PE is 
uncertain, but could eventually prevent trophoblast migration, normal syncytiotrophoblast turnover, 
promote syncytial degeneration and release vasoactive or inflammatory factors into the maternal 
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circulation (7). PE is also associated with exaggerated levels of cell-free foetal DNA and 
syncytiotrophoblast microparticles (STBM) which show characteristics of apoptosis in the maternal 
circulation (66-69). It is hypothesised that STBMs as well as cell-free foetal DNA could be released as 
a result of apoptotic cell death, this is supported by studies demonstrating increased levels of STBMs 
and cell-free foetal DNA in trophoblast cultured in conditions of hypoxia and H/R (70-72). Moreover, 
STBMs found in the maternal circulation are associated with an altered immunological response. In 
specific, neutrophil activation (73, 74) and the release of superoxide radicals (75). Furthermore, in vitro 
STBMs can disrupt endothelial cells, providing a link between placental apoptosis, STBM liberation 
and the maternal vascular complications which are characteristic of the pre-eclamptic syndrome (76, 
77).  
The elevation of p53 in pre-eclamptic women suggest that p53 is being released into the maternal 
circulation. Furthermore, altered apoptosis in pre-eclampsia is not only found in the placenta but in the 
endothelial cells (78). This may occur from the toxicity effect of excessive syncytial fragments or from 
the local hypoxic environment, and this effect may occur via p53-mediated endothelial apoptosis as 
seen in other systems (79, 80). It was also shown that the upregulation of p53 induced apoptosis and 
suppressed endothelial cell proliferation in PE (37).  
Conclusion 
In summary, we demonstrate a significant increase in p53 expression with a slight increase in JNK in 
PE, suggesting a potential role in the pathogenesis of PE. A significant down regulation of p53 with 
concurrent decrease of JNK was noted in the HIV positive group, indicating that HIV infection might 
offer a protective effect against exaggerated levels of p53 and JNK, however altered levels might be 
associated with use of HAART, which merits further investigation. The increase in expression of p53 
and JNK in PE elucidates their potential value as a risk indicator in the development of PE.  
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SYNTHESIS 
In South Africa, during 2011-2013 there were 4452 maternal deaths which is unacceptably high despite 
numerous health care improvements. The top 3 causes include non-pregnancy related infections (mainly 
HIV related complications) (34.7%), obstetric haemorrhage (15.8%) and 14.8% accounting for 
hypertension (South African Department of Health, 2013). Both, HIV infection and hypertensive 
disorders of pregnancies, especially pre-eclampsia (PE) are important conditions in developing 
countries (Hall et al., 2014). 
Despite decades of research the exact mechanism underlying the cause and progression of PE remains 
unknown and no successful treatment for PE is available currently except delivery of the placenta and 
baby (Williamson et al., 2017). A common concept is that immune maladaptation to the foetal allograft 
can result in impaired trophoblast invasion and defective spiral arterial remodelling (Matthiesen et al., 
2005, Dekker and Sibai, 1998). In normal placentation the extravillous cytotrophoblasts invade the 
uterine spiral arteries of the decidua and myometrium, replacing the endothelial layer of the maternal 
spiral arteries, transforming them from small, high-resistance vessels to high capacitance, low resistance 
vessels that can sustain the growth of the foetus (Wang et al., 2009). In PE remodelling of the spiral 
arteries is inadequate and limited to the decidua (Wang et al., 2009).  
The reduced utero placental perfusion secondary to abnormal placentation leads to placental ischemia 
and hypoxia (Levy, 2005). Retention of vasoreactivity of the spiral arteries could persist, resulting in 
intermittent perfusion, transient hypoxia, and ischemia-reperfusion insult of the villus (Hung et al., 
2001), which in turn releases cytokines as well as other inflammatory factors and damaging levels of 
reactive oxygen species (ROS) (Sánchez-Aranguren et al., 2014). Oxidative stress is observed when the 
relative pro-oxidant species (ROS) are higher than the antioxidant defences (Sánchez-Aranguren et al., 
2014), this can trigger a redox signalling process that induces cell apoptosis (Sánchez-Aranguren et al., 
2014). 
Apoptosis (programmed cell death), is important in the normal development of the placenta, however 
apoptosis is exaggerated in PE and initiated by various stimuli, including hypoxia and oxidative stress 
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(Sharp et al., 2010).  Important cell signalling molecules involved in the regulation of apoptosis include 
tumour protein p53 (Prives and Hall, 1999) and c-Jun N-terminal Kinase (JNK) (Lin and Dibling, 2002, 
Liu J and A., 2005). 
p53 is a transcription factor (Lane, 1992) and contributes to the regulation of proliferation, DNA repair, 
apoptosis, and survival (Sharp et al., 2014, Vousden and Ryan, 2009). Under normal conditions, the 
expression of p53 is kept at low levels, restrained by the ubiquitin ligase, murine double minute 2 
(Mdm2) which targets it for ubiquitination via the proteasome and removes it from the nucleus (Haupt 
et al., 1997, Kubbutat et al., 1997, Momand et al., 1992, Levine, 1997, Lu et al., 2000). 
Furthermore, p53 also promotes the transcription of Mdm2 (Harris and Levine, 2005). Stresses 
including heat, hypoxia, and cytokines promote DNA damage (Sharp, 2011, Harris and Levine, 2005), 
subsequently causing the phosphorylation of p53 at several sites, allowing for the stabilization of p53 
by inhibition of the p53-MDM2 interaction (Kruse and Gu, 2008). This results in the rapid increase of 
cellular p53 (Sharp, 2011). 
The results of this study demonstrate an upregulation of p53 in women with PE compared to 
normotensive pregnant women regardless of HIV status (HIV positive vs HIV negative). Similar 
findings of elevated p53 in PE has been observed in previous studies using placental tissue samples 
(Levy et al., 2002, Sharp et al 2014).  Hypoxia and oxidative stress could explain the stimulation and 
increase of p53 expression associated with apoptosis in PE in our study (Sharp et al., 2014). In support 
of this, studies have reported an association between exposure of trophoblasts to hypoxia and enhanced 
apoptosis (Levy et al., 2000), with an increase in the expression of p53 (Levy et al., 2000), Bax (Levy 
et al., 2000), and Mtd-1 (Soleymanlou et al., 2005) and a simultaneous decrease in anti-apoptotic Bcl-
2 expression (Levy et al., 2000, Hu et al., 2006). 
Apoptosis is initiated via the intrinsic or extrinsic pathway. Hypoxia (Levy, 2005), and ROS are able to 
trigger apoptosis via the intrinsic pathway, the activation of which leads to an altered mitochondrial 
membrane permeability due to the imbalance in the relationship of pro-apoptotic (Bax, Bak tBid, Bim, 
Puma, Noxa and Bad) and anti-apoptotic (Bcl-2, Bcl-xL and Mcl-1) Bcl-2 proteins (Cory and Adams, 
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2002, Vaseva and Moll, 2009). The resulting mitochondrial membrane permeability causes pore 
formation and cytochrome-c to leak into the cytosol where it binds with apoptosis protease activating 
factor-1 (APAF-1) and the initiator caspase 9 in the cytosol to form the apoptosome complex (Li et al., 
1997, Ott et al., 2002, Chinnaiyan, 1999). Both pathways culminate in a terminal pathway involving 
the activation of caspase-3, 6 and 7 that initiate cell destruction (Sharp et al., 2010, Tewari et al., 1995, 
Koh et al., 2005).  
p53 can induce apoptosis by promoting the downstream transcription of elements involved in apoptosis 
such as Bax, Noxa, Puma, Bid (Sharp, 2011), Mtd (Yakovlev et al., 2004) and APAF-1 in the nucleus 
or by directly permeabilizing mitochondria in the cytoplasm by acting as a pro-apoptotic BH3-only 
protein (Green and Kroemer, 2009). 
Mitogen activated protein kinases (MAPKs) are well known mediators in signal transduction pathways 
(Qi and Elion, 2005). These mediators are activated by phosphorylation (Cindrova-Davies, 2009). JNK 
is part of the MAPK family which are associated with the regulation of cell proliferation, differentiation, 
and apoptosis (Dhanasekaran and Reddy, 2008). JNK can be activated by various stimuli which include; 
growth factors (Hibi et al., 1993), cytokines (Westwick et al., 1994) and ROS (Chambers and LoGrasso, 
2011). 
When activated JNK can phosphorylate and regulate the activity of transcription factors such as; c-Jun, 
ATF2, Elk-1, and p53 (Chang and Karin, 2001, Davis, 2000, Karin, 1995, Lin, 2003) and other factors 
like the members of the Bcl-2 family (Bcl-2, Bcl-xL, Bim and BAD) (Liu J and A., 2005). JNK initiates 
apoptosis by increasing the expression of pro-apoptotic genes in the nucleus like TNF-a, Fas-L, and 
Bak (Fan and Chambers, 2001). Alternatively, activated JNK can translocate to the mitochondria where 
it modulates the activity of pro-apoptotic Bcl-2 proteins. (Dhanasekaran and Reddy, 2008). 
In this study, the expression of JNK was similar according to pregnancy type regardless of HIV status. 
Similar to our findings, Szabo et al evaluated JNK immunostaining of the villous trophoblast and 
showed no change in the JNK immunoscore in preterm or term PE, however it tended to be higher in 
late-onset PE compared to term controls (Szabo et al., 2015). A limitation of our study was the 
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heterogeneity of the pre-eclampsia cohort. Further studies are underway to sub-stratify PE into early-
onset pre-eclampsia (EOPE) and late-onset pre-eclampsia (LOPE) to maintain a homogenous 
population.  
EOPE is considered more severe than LOPE and originates from poor placentation, while LOPE seems 
to be exaggerated by predisposing risks for maternal endothelial dysfunction in the second half of 
pregnancy. Both types show enhanced systemic inflammatory responses (Herzog et al., 2017). Separate 
pathogenic paths for EOPE and LOPE have been proposed. The distinction could thus lead to different 
approaches in clinical management (Chen et al., 2012). A study has shown that the shedding of cell-
free foetal DNA syncytiotrophoblast microparticles (STBMs) into the maternal circulation occurs in 
greater amounts in EOPE vs LOPE (Chen et al., 2012).  
The upregulation in our study observed may be attributed to the increased hypoxia and oxidative stress 
in PE (Sharp et al., 2010). Studies supporting this show that placental explants challenged with different 
pre-eclamptic associated stresses such as hypoxia-reoxygenation (H/R) (Cindrova-Davies et al., 2007), 
hypoxia and inflammatory cytokines (Xiong et al., 2013) lead to increased oxidative stress and 
subsequent phosphorylation of JNK with the resultant activation of the JNK/MAPK pathway 
(Cindrova-Davies et al., 2007, Xiong Y et al., 2013).  
In our study, a significant difference in the expression of p53 based on HIV status (HIV positive vs HIV 
negative) was observed, with a downregulation in the level of p53 in the HIV positive compared to the 
HIV negative group. These results could be due to the neutralisation of the immune response expected 
in HIV associated PE (Hall et al., 2014). Furthermore, the HIV accessory protein, Nef interacts directly 
with p53, Nef could therefore supplement HIV replication by extending infected cell sustainability by 
blocking p53-mediated apoptosis (Greenway et al., 2002). This indicates that HIV infection might have 
a protective effect in the pathogenesis of PE by reducing the level of p53. However, previous studies 
report that p53 may be activated in HIV-1 infection (Eduardo Pauls et al., 2006). Therefore, our results 
might be due to the use of HAART which suppresses HIV replication and exacerbates inflammatory 
response (Kusdra et al., 2002).  
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In normal pregnancy there is an upregulation of the immune response, in PE this upregulation is 
exacerbated leading to an excessive maternal inflammatory response. Therefore, in HIV infection which 
is a condition of immune deficiency, a neutralisation of the immune response is expected in HIV 
associated PE. (Hall et al., 2014) which could possibly explain our results. We also demonstrate a 
significant difference of p53 between HIV negative pre-eclamptic vs HIV negative normotensive. 
There was no significant difference demonstrated in the expression of JNK based on HIV status. 
However, a downregulation trend was seen in the HIV positive vs the HIV negative group. Other studies 
have reported that HIV-1 infection could activate the host cellular MAPK signalling pathway, 
enhancing the HIV-1 gene expression level, viral genome replication level and virus infection activity 
(Cohen et al., 1997, Jacque J M et al., 1998, Xiaoyu Yang and Gabuzda., 1998). Furthermore, a study 
by Gong et al showed that a JNK pathway inhibitor SP600125 had a slight effect on HIV infection and 
HIV-1 LTR promoter activity (Gong et al., 2011) supporting our results. A limitation of our study was 
that all HIV positive women in our study were on HAART or anti-retroviral drugs, as it is the standard 
of care in South Africa. HAART can re-constitute the mother’s immune response, and thus increase the 
risk of developing PE (Wimalasundera et al., 2002). 
Both hypoxia and oxidative stress may contribute to the increase of p53 and JNK which are implicated 
in the causation of the exaggerated apoptosis in PE. In PE, increased apoptosis is believed to result from 
intrinsic cell damage, hypothesized in vivo to result from hypoxia-reperfusion injury (Hung and Burton, 
2006), and replicated in vitro by hypoxia (Heazell et al., 2008b, Soleymanlou et al., 2007, Levy et al., 
2002) and oxidative stress (Hung et al., 2012, Hung et al., 2008) which could be the underlying cause 
in the pathophysiology of PE (Sharp et al., 2010).  
Exaggerated apoptosis could eventually prevent normal replenishment of the syncytiotrophoblast, 
promote syncytial degeneration and release vasoactive or inflammatory factors into the maternal 
circulation (Sharp et al., 2010). PE is associated with an elevation in STBMs which have features of 
apoptosis in the maternal circulation (Johansen et al., 1999, Goswami et al., 2006, Knight et al., 1998, 
Zhong et al., 2002). It is hypothesised that STBMs and cell-free foetal DNA may be released due to 
apoptotic cell death, supported by studies demonstrating increased levels of STBMs and cell-free foetal 
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DNA in trophoblast cultured in hypoxia and H/R (Abumaree et al., 2006, Orozco et al., 2006, Tjoa et 
al., 2006).   
STBMs found in the maternal circulation are associated with an altered immune response specifically, 
neutrophil activation (Von Dadelszen P et al., 1999, Gupta et al., 2006) and the release of superoxide 
radicals (Aly AS et al., 2004). Additionally, in vitro STBMs can disrupt endothelial cells, providing a 
connection between placental apoptosis, syncytial microparticle liberation and the maternal vascular 
complications which are characteristic of the pre-eclamptic syndrome (Cockell et al., 1997, Hoegh et 
al., 2006). 
Placental apoptosis as well as cytotrophoblast proliferation is enhanced. This imbalance may contribute 
to the pathogenesis of PE. Increased syncytiotrophoblast apoptosis counters cytotrophoblast fusion, 
thereby promoting the release of syncytial material which can disrupt the maternal vascular endothelium 
(Crocker, 2007). A study by Jeschke et al, shows elevated proliferation of villous trophoblastic cells in 
HELLP placentas is accompanied with an elevation of p53 expression (Jeschke et al., 2006).  
Endothelial cells have a role in fluid filtration, homeostasis, hormone trafficking and regulating vascular 
tone. In a study by Gao et al, an upregulation of p53 induced apoptosis and suppressed endothelial cell 
proliferation in PE, therefore, these mechanisms could result in impaired regulation of vasodilation and 
vasoconstriction, as well as angiogenesis which could aggravate PE (Gao et al, 2016).   
These results suggest that elevated levels of p53 and JNK could be released from the placenta into the 
maternal circulation in PE, and inhibited by HIV infection as a downregulation trend of p53 and JNK 
was seen, Further studies need to be conducted examining the expression of p53 and JNK in HIV 
associated PE using placental tissue samples.  
The constant generation of potentially damaging oxygen radicals are controlled by anti-oxidants like 
vitamin C, vitamin E and glutathione. However, these defences are not flawless, and when there is an 
imbalance between the relative pro-oxidant species (ROS) and anti-oxidants, a state of oxidative stress 
is reached (Cindrova-Davies, 2009, Sánchez-Aranguren et al., 2014). Also, antioxidant vitamins C and 
E effectively suppressed markers of oxidative stress, apoptosis as well as phosphorylation of JNK 
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induced by H/R (Cindrova-Davies et al., 2007). Due to multiple different mechanisms contributing to 
the development of apoptosis, further studies are needed to clarify the signalling mechanisms of 
apoptosis in PE before therapeutic treatments can be employed (Levy, 2005).  
In conclusion, this study demonstrates a significant increase in p53 expression whilst JNK showed an 
up-regulation trend in PE, regardless of HIV status. These results support the role for these cell 
signalling molecules in the pathogenesis of PE. However, based on HIV status a significant down 
regulation of p53 and a slight decrease of JNK was noted in HIV positive compared to HIV negative 
group indicating that HIV infection may offer a protective effect against the exaggerated apoptosis 
associated with PE, however these altered levels may be attributes to HAART. Notably the increase in 
expression of p53 and JNK in PE, embraces their potential value as a risk indicator in the development 
of PE, hence further research in this regard is required.  
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